Clarus Therapeutics is a pharmaceutical company developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications.
Clarus Therapeutics became a publicly listed company on September 9, 2021 after completing a business combination with Blue Water Acquisition, a publicly traded special purpose acquisition company. Forge no longer actively tracks this company.
